ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: SA-PO009

In Vitro Effect of Cartridge Functionalized With Antibiotic on a Bacterial Population in Hemoperfusion Treatment

Session Information

  • Bioengineering
    November 05, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
    Abstract Time: 10:00 AM - 12:00 PM

Category: Bioengineering

  • 300 Bioengineering


  • de Cal, Massimo, Ospedale San Bortolo di Vicenza, Vicenza, Italy
  • Lorenzin, Anna, Ospedale San Bortolo di Vicenza, Vicenza, Italy
  • Ronco, Claudio, Ospedale San Bortolo di Vicenza, Vicenza, Italy
  • Zanella, Monica, Ospedale San Bortolo di Vicenza, Vicenza, Italy

HA380 (Jafron, China) is an hemoperfusion (HP) cartridge applied in septic patients that often developed AKI. We have demonstrated that vancomycin (Van) is absorbed by HA380 during in vitro HP. We recreated an in vitro HP treatment in presence of bacteria to assess the effect of cartridge pre-treated with Van solution.


We compared the effect of 2 mini-modules of the HA380 cartridge. Saline solution enriched with 1g of Van was circulated in HP in one of the cartridges and 545mg of antibiotic were adsorbed by the sorbent beads.
We injected 106 S.aureus bacteria sensitive to Van in 800mL of blood and incubated at 37°C. After 24h blood was partitioned into 3 reservoirs: 200mL were maintained as a negative control; 300mL were circulated in the mini-module previously used with Van solution; 300mL in the other cartridge.
The circulations were performed, simultaneously, in a closed-loop at 250mL/min with a dedicate testing platform for 120 minutes (Figure). Blood was maintained at 37°C and stirred.
Blood samples were drawn at T0 (before partition), T1 and T2 (after 1 and 2 hours of circulation) from the 3 reservoirs. Samples were cultured in cna agar plates to assess the bioburden and in DB Bactec bottles to estimate the time after which the bacteria replication reaches the predetermined growth threshold.


At T0, T1 and T2 in negative control and in the mini-module without antibiotic, growth of bacteria was detected at 1h and 30 minutes and plates showed 2x106 bacteria. At T1 and T2 in the mini-module with Van, growth was detected respectively at 7h and 8h and plates showed 106 bacteria.


The functionalized mini-module has been more effective in the reduction of the bioburden as the bound Van could be still active.

Figure: Experimental set-up of the HP treatments.